Results 141 to 150 of about 23,251 (242)

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 9, Page 1467-1473, September 2026.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi   +7 more
wiley   +1 more source

Wnt3a Downregulation Contributes to Type 2 Diabetes Mellitus by Impairing Pancreatic β‐Cell Function

open access: yesThe FASEB Journal, Volume 40, Issue 16, 31 August 2026.
Wnt3a downregulation is associated with type 2 diabetes mellitus (T2DM) in clinical patients and high‐fat diet (HFD)‐induced mouse models. In MIN6 pancreatic β‐cells, knockdown of Wnt3a impairs insulin secretion and β‐cell function under insulin‐resistant conditions, while recombinant Wnt3a treatment rescues these defects.
Yilinuer Adeerjiang   +4 more
wiley   +1 more source

The effect of ketosis on the FRDA phenotypes

open access: yes
Friedreich ataxia (FRDA) is an autosomal recessive neurodegenerative disease characterized by progressive gait and limb ataxia, cerebellar, pyramidal and dorsal column involvement, vision loss, scoliosis and cardiac abnormalities.
An, Jacob   +6 more
core   +1 more source

<i>HLA-DRB1*08:03</i>-associated exocrine-endocrine immune linkage: a pathogenic mechanism in ketosis-prone type 2 diabetes. [PDF]

open access: yesJ Endocr Soc
Suzuki S   +8 more
europepmc   +1 more source

From Disease Silos to Integrated Cardiometabolic Care: Diabetes, Vascular Disease, and Heart Failure

open access: yes
Journal of Diabetes, Volume 18, Issue 9, September 2026.
Zachary T. Bloomgarden   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy